Journal: PLOS One
Article Title: Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023
doi: 10.1371/journal.pone.0323843
Figure Lengend Snippet: (A) Optum CDM (2023), (B) MORE 2 Registry (2022), and (C) Medicare FFS (2021). CAD, cold agglutinin disease; FFS, Fee for Service; MORE 2 , Medical Outcomes Research for Effectiveness and Economics; Optum CDM, Optum de-identified Clinformatics ® Data Mart; US, United States. AK, Alaska; AL, Alabama; AR, Arkansas; AZ, Arizona; CA, California; CO, Colorado; CT, Connecticut; DC, District of Columbia; DE, Delaware; FL, Florida; GA, Georgia; HI, Hawaii; IA, Iowa; ID, Idaho; IL, Illinois; IN, Indiana; KS, Kansas; KY, Kentucky; LA, Louisiana; MA, Massachusetts; MD, Maryland; ME, Maine; MI, Michigan; MN, Minnesota; MO, Missouri; MS, Mississippi; MT, Montana; NC, North Carolina; ND, North Dakota; NE, Nebraska; NH, New Hampshire; NJ, New Jersey; NM, New Mexico; NV, Nevada; NY, New York; OH, Ohio; OK, Oklahoma; OR, Oregon; PA, Pennsylvania; RI, Rhode Island; SC, South Carolina; SD, South Dakota; TN, Tennessee; TX, Texas; UT, Utah; VA, Virginia; VT, Vermont; WA, Washington; WI, Wisconsin; WV, West Virginia; WY, Wyoming.
Article Snippet: This retrospective study aims to update the epidemiology of AIHA and CAD in the US from 2016 to 2023 by separately analyzing administrative claims data from Optum’s de-identified Clinformatics ® Data Mart (Optum CDM), Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE 2 ) Registry, and Medicare Fee for Service (FFS).
Techniques: